Jennifer Felger
Emory University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
5
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
NIH RePORTER
Trial papers
11
PubMed author-name match
Trials
Studies that name Jennifer Felger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07003997 · JAK Signaling in DepressionEmory University · recruiting · Major Depressive Disorder · principal investigator
- Ph4NCT06075771 · Dopaminergic Therapy for Anhedonia - 2Emory University · recruiting · Anhedonia, Depression · principal investigator
- Ph2NCT05849038 · Inflammation and Depression in People With HIVEmory University · recruiting · HIV, Depression, Anhedonia · principal investigator
- Ph4NCT04723147 · DTA (Dopaminergic Therapy for Anhedonia) StudyEmory University · completed · Depression, Anhedonia · principal investigator
- Ph4NCT02513485 · Inflammation-related Alterations in Neurocircuitry: Reversal With LevodopaEmory University · completed · Depression · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in DepressionR01MH140180 · NIMH · EMORY UNIVERSITY · fiscal years 2025 to 2026 · $627,566 awarded in 2026Grant number is on one of their registry trials
- The Role of Inflammation in CNS Mechanisms of Anhedonia and Psychomotor Slowing in Depressed PWH as Determined using a Next Generation TNF AntagonistR01MH128872 · NIMH · EMORY UNIVERSITY · fiscal years 2021 to 2026 · $618,864 awarded in 2026Grant number is on one of their registry trials
- Dopaminergic Therapy for Inflammation-Related Anhedonia in DepressionR33MH121625 · NIMH · EMORY UNIVERSITY · fiscal years 2023 to 2025 · $696,294 awarded in 2025Grant number is on one of their registry trials
- Effects of Bupropion versus Escitalopram on Reward Circuitry and Motivational Deficits in Patients with Major Depression and Increased Inflammation and AnhedoniaR21MH121891 · NIMH · EMORY UNIVERSITY · fiscal years 2020 to 2021 · $234,000 awarded in 2021Same name and institution; not confirmed by an ID
- Dopaminergic Therapy for Inflammation-Related Anhedonia in DepressionR61MH121625 · NIMH · EMORY UNIVERSITY · fiscal years 2020 · $1,406,314 awarded in 2020Grant number is on one of their registry trials
- Inflammation Effects on Corticostriatal Connectivity and Reward: Role of DopamineR01MH109637 · NIMH · EMORY UNIVERSITY · fiscal years 2016 to 2019 · $527,948 awarded in 2019Grant number is on one of their registry trials
- Neurobiology of cytokine effects on CNS glutamate in IFN-alpha-induced depressionR21MH106904 · NIMH · EMORY UNIVERSITY · fiscal years 2015 to 2016 · $195,000 awarded in 2016Same name and institution; not confirmed by an ID
- Cytokine Effects on Amphetamine-Induced Dopamine Release using PET NeuroimagingF32MH093054 · NIMH · EMORY UNIVERSITY · fiscal years 2010 to 2011 · $58,113 awarded in 2011Same name and institution; not confirmed by an ID
- Cytokine-induced Behavioral AlterationsF31MH073355 · NIMH · EMORY UNIVERSITY · fiscal years 2004 to 2006 · $17,157 awarded in 2006Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:34 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.Mol Psychiatry · 202298 citationsRCR 9.0
- Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.Brain Behav Immun · 201568 citationsRCR 2.6
- Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.Brain Behav Immun · 201366 citationsRCR 2.2
- Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.Prostaglandins Leukot Essent Fatty Acids · 202153 citationsRCR 3.8
- Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial.J Clin Psychiatry · 202248 citationsRCR 4.7
- Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.Psychol Med · 201246 citationsRCR 1.5
- A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation.Mol Psychiatry · 202538 citationsRCR 12.8
- Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue.Brain Behav Immun · 201135 citationsRCR 1.1
- Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators.Neuropsychopharmacology · 202324 citationsRCR 2.9
- Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation.Brain Behav Immun · 202521 citationsRCR 8.3